HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy

Molecular Therapy

Volumn 21, Issue 4, 2013, Pages 887-894

  Bridle, Byram W ^a   Chen, Lan ^b   Lemay, Chantal G ^c   Diallo, Jean Simon ^c   Pol, Jonathan ^a   Nguyen, Andrew ^a   Capretta, Alfredo ^a   He, Rongqiao ^b   Bramson, Jonathan L ^a   Bell, John C ^c   Lichty, Brian D ^a   Wan, Yonghong ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b INSTITUTE OF BIOPHYSICS   (China)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; IMMUNE RESPONSE; LYMPHOCYTOPENIA; MELANOMA; MOUSE; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIMARY IMMUNE RESPONSE; REGULATORY T LYMPHOCYTE; SECONDARY IMMUNE RESPONSE;

EID: 84878621268     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.265     Document Type: Article

References (50)

1. Barber, GN (2005). VSV-tumor selective replication and protein translation. Oncogene 24: 7710-7719.
2. Parato, KA, Senger, D, Forsyth, PA and Bell, JC (2005). Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 5: 965-976.
3. Stojdl, DF, Lichty, B, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specifc defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825.
4. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
5. Alain, T, Lun, X, Martineau, Y, Sean, P, Pulendran, B, Petroulakis, E et al. (2010). Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 107: 1576-1581.
6. Diallo, JS, Le Boeuf, F, Lai, F, Cox, J, Vaha-Koskela, M, Abdelbary, H et al. (2010). A high-throughput pharmacoviral approach identifes novel oncolytic virus sensitizers. Mol Ther 18: 1123-1129.
7. Chang, HM, Paulson, M, Holko, M, Rice, CM, Williams, BR, Marié, I et al. (2004). Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 101: 9578-9583.
8. Minucci, S and Pelicci, PG (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38-51.
9. Nusinzon, I and Horvath, CM (2006). Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 26: 3106-3113.
10. Nguyên, TL, Abdelbary, H, Arguello, M, Breitbach, C, Leveille, S, Diallo, JS et al. (2008). Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 105: 14981-14986.
11. Blanchard, F and Chipoy, C (2005). Histone deacetylase inhibitors: new drugs for the treatment of infammatory diseases? Drug Discov Today 10: 197-204.
12. Choi, S and Reddy, P (2011). HDAC inhibition and graft versus host disease. Mol Med 17: 404-416.
13. Haberland, M, Montgomery, RL and Olson, EN (2009). The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42.
14. Shakespear, MR, Halili, MA, Irvine, KM, Fairlie, DP and Sweet, MJ (2011). Histone deacetylases as regulators of infammation and immunity. Trends Immunol 32: 335-343.
15. Bridle, BW, Stephenson, KB, Boudreau, JE, Koshy, S, Kazdhan, N, Pullenayegum, E et al. (2010). Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther 18: 1430-1439.
16. Lun, X, Senger, DL, Alain, T, Oprea, A, Parato, K, Stojdl, D et al. (2006). Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst 98: 1546-1557.
17. Kamphuis, E, Junt, T, Waibler, Z, Forster, R and Kalinke, U (2006). Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
18. McNally, JM, Zarozinski, CC, Lin, MY, Brehm, MA, Chen, HD and Welsh, RM (2001). Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses. J Virol 75: 5965-5976.
19. Suzuki, T, Ando, T, Tsuchiya, K, Fukazawa, N, Saito, A, Mariko, Y et al. (1999). Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives. J Med Chem 42: 3001-3003.
20. Schattner, A, Meshorer, A and Wallach, D (1983). Involvement of interferon in virus-induced lymphopenia. Cell Immunol 79: 11-25.
21. Chauhan, SK, Saban, DR, Lee, HK and Dana, R (2009). Levels of Foxp3 in regulatory T cells refect their functional status in transplantation. J Immunol 182: 148-153.
22. d'Hennezel, E, Yurchenko, E, Sgouroudis, E, Hay, V and Piccirillo, CA (2011). Single-cell analysis of the human T regulatory population uncovers functional heterogeneity and instability within FOXP3+ cells. J Immunol 186: 6788-6797.
23. MacTavish, H, Diallo, JS, Huang, B, Stanford, M, Le Boeuf, F, De Silva, N et al. (2010). Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS ONE 5: e14462.
24. Dondi, E, Rogge, L, Lutfalla, G, Uzé, G and Pellegrini, S (2003). Down-modulation of responses to type I IFN upon T cell activation. J Immunol 170: 749-756.
25. Gil, MP, Salomon, R, Louten, J and Biron, CA (2006). Modulation of STAT1 protein levels: a mechanism shaping CD8 T-cell responses in vivo. Blood 107: 987-993.
26. Marshall, HD, Urban, SL and Welsh, RM (2011). Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol 85: 5929-5939.
27. Peacock, CD, Kim, SK and Welsh, RM (2003). Attrition of virus-specifc memory CD8+ T cells during reconstitution of lymphopenic environments. J Immunol 171: 655-663.
28. Jiang, J, Lau, LL and Shen, H (2003). Selective depletion of nonspecifc T cells during the early stage of immune responses to infection. J Immunol 171: 4352-4358.
29. Yamaguchi, T, Cubizolles, F, Zhang, Y, Reichert, N, Kohler, H, Seiser, C et al. (2010). Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 24: 455-469.
30. Cui, Y, Zhang, H, Meadors, J, Poon, R, Guimond, M and Mackall, CL (2009). Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 114: 3831-3840.
31. Melchionda, F, Fry, TJ, Milliron, MJ, McKirdy, MA, Tagaya, Y and Mackall, CL (2005). Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J Clin Invest 115: 1177-1187.
32. Seder, RA, Darrah, PA and Roederer, M (2008). T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
33. Weber, J, Atkins, M, Hwu, P, Radvanyi, L, Sznol, M and Yee, C; Immunotherapy Task Force of the NCI Investigational Drug Steering Committee (2011). White paper on adoptive cell therapy for cancer with tumor-infltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 17: 1664-1673.
34. Antony, PA, Piccirillo, CA, Akpinarli, A, Finkelstein, SE, Speiss, PJ, Surman, DR et al. (2005). CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174: 2591-2601.
35. Shen, L, Ciesielski, M, Ramakrishnan, S, Miles, KM, Ellis, L, Sotomayor, P et al. (2012). Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE 7: e30815.
36. Bouaziz, JD, Yanaba, K and Tedder, TF (2008). Regulatory B cells as inhibitors of immune responses and infammation. Immunol Rev 224: 201-214.
37. Andreu, P, Johansson, M, Affara, NI, Pucci, F, Tan, T, Junankar, S et al. (2010). FcRgamma activation regulates infammation-associated squamous carcinogenesis. Cancer Cell 17: 121-134.
38. Caspi, RR (2008). Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 8: 970-976.
39. Gilboa, E (2001). The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2: 789-792.
40. Koon, H and Atkins, M (2006). Autoimmunity and immunotherapy for cancer. N Engl J Med 354: 758-760.
41. Nanda, NK and Sercarz, EE (1995). Induction of anti-self-immunity to cure cancer. Cell 82: 13-17.
42. Overwijk, WW and Restifo, NP (2000). Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol 20: 433-450.
43. Bridle, BW, Li, J, Jiang, S, Chang, R, Lichty, BD, Bramson, JL et al. (2010). Immunotherapy can reject intracranial tumor cells without damaging the brain despite sharing the target antigen. J Immunol 184: 4269-4275.
44. Lane, C, Leitch, J, Tan, X, Hadjati, J, Bramson, JL and Wan, Y (2004). Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 64: 1509-1514.
45. Lang, KS, Recher, M, Junt, T, Navarini, AA, Harris, NL, Freigang, S et al. (2005). Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11: 138-145.
46. Adcock, IM (2006). Histone deacetylase inhibitors as novel anti-infammatory agents. Curr Opin Investig Drugs 7: 966-973.
47. Nencioni, A, Beck, J, Werth, D, Grünebach, F, Patrone, F, Ballestrero, A et al. (2007). Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 13: 3933-3941.
48. Zhang, ZY, Zhang, Z and Schluesener, HJ (2010). MS-275, an histone deacetylase inhibitor, reduces the infammatory reaction in rat experimental autoimmune neuritis. Neuroscience 169: 370-377.
49. Lin, HS, Hu, CY, Chan, HY, Liew, YY, Huang, HP, Lepescheux, L et al. (2007). Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 150: 862-872.
50. Power, AT, Wang, J, Falls, TJ, Paterson, JM, Parato, KA, Lichty, BD et al. (2007). Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 15: 123-130.